# The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

> **NCT00674453** · PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Bone Loss

## Interventions

- **DRUG:** Lasofoxifene
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00674453
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2011-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674453, "The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00674453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*